share_log

ProSomnus | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

SEC announcement ·  Feb 13 11:59
Summary by Moomoo AI
On February 12, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This amendment is intended to convert the existing registration statement into a registration statement on Form S-3 and to remove from registration the Convertible Note Shares that were previously registered, of which 230,494 have been sold. The company also announced a primary offering of up to 8,923,935 shares of common stock upon the exercise of warrants and a secondary offering of up to 9,850,363 shares of common stock and up to 2,411,848 warrants. The warrants, exercisable at $11.50 per share, include Public Warrants, Private Warrants, and Convertible Note Warrants. ProSomnus, a manufacturer of oral appliance therapy devices for obstructive sleep apnea, will not receive proceeds from the sale of securities by the Selling Securityholders, except for potential proceeds from the exercise of warrants. The company's common stock and public warrants are listed on the Nasdaq under the symbols 'OSA' and 'OSAAW,' respectively.
On February 12, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This amendment is intended to convert the existing registration statement into a registration statement on Form S-3 and to remove from registration the Convertible Note Shares that were previously registered, of which 230,494 have been sold. The company also announced a primary offering of up to 8,923,935 shares of common stock upon the exercise of warrants and a secondary offering of up to 9,850,363 shares of common stock and up to 2,411,848 warrants. The warrants, exercisable at $11.50 per share, include Public Warrants, Private Warrants, and Convertible Note Warrants. ProSomnus, a manufacturer of oral appliance therapy devices for obstructive sleep apnea, will not receive proceeds from the sale of securities by the Selling Securityholders, except for potential proceeds from the exercise of warrants. The company's common stock and public warrants are listed on the Nasdaq under the symbols 'OSA' and 'OSAAW,' respectively.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more